Purpose of review Allogeneic hematopoietic cell transplantation (HCT) is a life-saving therapy for hematological and nonhematological diseases. Cord blood is a source of transplantable hematopoietic stem cells (HSCs), but limited numbers of HSCs in single cord blood units, which may cause delayed neutrophil, platelet, and immune cell reconstitution, is a major problem for efficient transplantation. Ex-vivo expansion and enhanced homing of cord blood HSC may overcome this disadvantage and improve its long-term engraftment. Here, we discuss the role of nuclear hormone receptors signaling in human cord blood HSC engraftment.
INTRODUCTION
Homeostasis of hematopoiesis is maintained by intrinsic and extrinsic signals by hematopoietic stem cells (HSC) and hematopoietic progenitor cells (HPC), rare immature cell populations residing in microenvironmental niches [1] [2] [3] . HSC self-renew, or differentiate through HPC into all mature blood cells throughout [4] . Human HSC are major contributors for HCT [5, 6] . Once infused into peripheral blood of recipients, HSC and HPC migrate and engraft in bone marrow niches, wherever a new hematopoietic system builds up [7, 8] . Three major sources of HSC for HCT are: bone marrow, peripheral blood, and cord blood [9, 10] . Compared with the other sources, cord blood has advantages, including ready availability, less strict HLA-matching requirements, lower incidence of graft vs. host disease and virus infection, and low probability of relapse among patients with minimal residual disease [11] [12] [13] . However, delayed hematopoietic recovery and immune reconstitution because of limited numbers of HSCs are major limiting factors preventing the wider use of HCT-based cell therapy. Progress to improve cord blood HSC engraftment and reconstitution includes mitigating effects of Extra Physiologic Oxygen Shock/Stress (EPHOSS) during cell collection [14] , ex-vivo expansion of HSC [15, 16, 17 Nuclear hormone receptors are transcription factors, which regulate expression of target genes by binding to specific response elements in the transcription units [18, 19] . nuclear hormone receptor, consisting of 48 members in humans, are activated by steroid hormones such as glucocorticoids and estrogen, or nonsteroid hormones such as retinoic acid, vitamin D, and thyroid hormones. Nuclear hormone receptor members share a similar structure, composed of a highly variable A/B transactivation domain, a conserved DNA-binding domain (C domain), a nuclear localization signal containing D domain and a relatively conserved ligand-binding E domain [18, 19] . Upon ligand binding, the conformation of nuclear hormone receptor changes and a repressor complex such as NCoR and SMRT corepressor disassociate from nuclear hormone receptor, followed by recruitment of transactivation complexes with histone acetyltransferase (HAT) activity and other transcription machinery, thus facilitating transcription of target genes [20] . Nuclear hormone receptors are involved in physiological processes including: proliferation [21] , differentiation [22, 23] , development [24] , and metabolism [25, 26] . To treat diseases caused by dysfunction of nuclear hormone receptor, synthetic agonists and antagonists of nuclear hormone receptor were developed to modulate its activity [27] . These diversified synthetic ligands help explore novel biological functions of nuclear hormone receptor in humans.
Here, we summarize recent progress regarding enhancing human HSC and HPC engraftment by modulating nuclear hormone receptor signaling.
RETINOID ACID SIGNALING AND HUMAN HEMATOPOIETIC STEM CELL EXPANSION
Retinoid acid receptor (RAR) serves as the nuclear receptor for all-trans retinoid acid (ATRA), the biologically active form of retinol (vitamin A) [28] .There are three different subtypes of RAR (a, b, and g), and each is alternatively spliced into at least two distinct isoforms [29] . Although RAR is highly conserved between mouse and human, functioning of RAR signaling in murine and human HSC homeostasis is quite different. RARa knockout mice show no abnormal phenotype of HSCs and HPCs, while HSC numbers are significantly reduced in RARg knockout mouse bone marrow [30] . bone marrow HPC numbers are increased in RARg knockout mice compared with wild type animals, suggesting that RARg might regulate differentiation of their HSCs. Meanwhile, ATRA ex-vivo treatment enhances repopulating capability of murine bone marrow [30] . Physiological ATRA is derived from retinol, which is not synthesized by animals but is obtained from food (vegetables, fruits, and animal livers) [31] , so HSC homeostasis can be affected by availability of retinol in food. ATRA treatment protects dormant HSCs from stress-induced activation by restricting protein synthesis and reactive oxygen species (ROS) generation [32 && ]. Numbers of dormant HSCs in retinol-free diet-fed mice, in which the retinoid acid reservoir is depleted, is significantly reduced [32 && ]. RAR usually forms a heterodimer with retinoid X receptor (RXR) [33] . RXRa signaling negatively regulates granulocyte development from HSCs and HPCs in humans and mice [34] , whereas in-vivo hematopoiesis in RXRa knockout mice is normal [35] . As there are two other isoforms of RXR (RXRb and RXRg) [29] , normal hematopoiesis of RXRa knockout mice might be because of functional redundancy of different isoforms. It would be interesting to explore roles of RXR signaling in HSC self-renewal and maintenance using distinct RXR isoform double or triple knockout mice, as little is known of RXR in mouse and human HSC homeostasis.
Although activation of RAR signaling positively regulates development and function of mouse embryonic and adult HSC [30, 36, 37] , human cord blood HSC self-renewal appears negatively modulated by the RAR pathway. Aldehyde dehydrogenase (ALDH) is a key enzyme in the retinoid acid synthesis pathway in vivo, and is characterized as a marker of HSCs and other tissue stem cells [38] [39] [40] . There are many ALDH isoforms. ALDH1 is considered the major isoform in HSCs and HPCs [41, 42] . Treatment of human bone marrow and cord blood
KEY POINTS
Antagonizing RAR signaling increases myeloid cell production and promotes human HSC expansion and engraftment by inhibiting differentiation.
Attenuating AhR signaling enhances human HSC expansion, and SR1-expanded HSCs and HPCs show significant faster recovery of neutrophils and platelets in clinical study of HCT.
Glucocorticoid pretreatment of human HSCs and HPCs enhances their homing and engraftment capability in NSG mice.
PPARg antagonism promotes self-renewal and engraftment of human HSCs and HPCs by switching on FBP1-repressed glucose metabolism and preventing differentiation. PPARg is ectopically activated in primary fanconi patient samples, and PPARg signaling might be an effective target in therapy of fanconi patients.
CD34
þ CD38 À cells with diethylaminobenzaldehyde (DEAB), an ALDH inhibitor, enhances expansion and maintenance of HSCs and HPCs, as well as the in-vivo frequency of severe combined immunodeficiency (SCID)-repopulating cells (SRCs) in immune-compromised NOD/SCID mice [42] . Enhanced expansion of HSCs by DEAB can be reversed by retinoic acid-induced differentiation [42] . Although HSCs themselves have the capability to convert retinol to retinoic acid [43] , it would be interesting to determine whether inhibition of ALDH in HSCs or HPCs leads to down-regulation of retinoic acid signaling, and thus stimulates human HSC expansion and maintenance. Bone marrow stromal cells secrete CYP26 in the serum to inactivate and prevent retinoic acid signaling, and thus regulate human HSC self-renewal [44] , suggesting that modulating retinoic acid signaling by targeting microenvironmental niches represents a promising way to enhance ex-vivo human HSC expansion. Treatment of CD34
þ CD38 À cells with LG1506, a selective RXR modulator, enhances human HSC and HPC expansion and long-term engraftment in NOD/SCID mice [45] . Mechanistically, once binding with LG1506, the RXR-RAR complex recruits silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressors to promoters of target genes such as CD38, thus inhibiting differentiation of HSCs [45] . Recently, it was found that RARa antagonist increases myeloid cell production and promotes expansion of human HSCs, whereas RARg antagonist had no effect because of different sensitivity to ATRA [46] . RXR forms heterodimers with other nuclear hormone receptors, including liver X receptor (LXR), thyroid hormone receptor (THR), vitamin D receptor (VDR), and peroxisome proliferator-activated receptors (PPARs). Future studies should characterize roles of these RXR heterodimers in human HSC maintenance and engraftment.
GLUCOCORTICOID SIGNALING IN HOMING AND ENGRAFTMENT OF HUMAN HEMATOPOIETIC STEM CELLS
Glucocorticoid receptors, members of the steroid nuclear hormone receptor subfamily, which also includes mineralocorticoid receptor, estrogen receptor, androgen receptor, and progestogen receptor [18] . Unliganded glucocorticoid receptor resides in the cytoplasm and is complexed with HSP90 and HSP70 [47] . Upon binding with glucocorticoid, glucocorticoid receptor translocates into the nucleus and binds to glucocorticoid response elements (GREs) in transcription units of target genes [48] . Co-activators such as SRC-1and CBP/p300 are recruited by activated glucocorticoid receptor, thus facilitating transcription of target genes [48] . Glucocorticoid/glucocorticoid receptor signaling is involved in many physiological processes, including carbohydrate metabolism, energy homeostasis, development, and immune function [47] . Glucocorticoid levels are controlled by hypothalamic-pituitary-adrenal (HPA) axis in vivo [47] . In mouse and rat, the major endogenous glucocorticoid is corticosterone, whereas in primates including humans, the endogenous active glucocorticoid is cortisol (or hydrocortisone) [49] . There are many synthetic glucocorticoids, such as dexamethasone, prednisone, and fluticasone, which have been widely used as Food and Drug Administration (FDA)-approved drugs for anti-inflammation, allergy, or asthma [47, 50] .
Glucocorticoids regulate erythropoiesis. Co-culture with glucocorticoids in vitro promotes proliferation of erythroid progenitors [51] ; in vivo, glucocorticoid receptor signaling is essential for stress-induced expansion of erythroid progenitors [51] . Glucocorticoid receptor synergizes with PPARa promoting self-renewal of erythroid progenitor cells [52] . Glucocorticoid/glucocorticoid receptor signaling also plays pivotal roles in HSC homeostasis, including HSC production, HSC mobilization, and HSC homing. ]. Upon glucocorticoid treatment, cytoplasmic glucocorticoid receptor in cord blood HSCs and HPCs was activated. Activated glucocorticoid receptor translocated into the nucleus and bound to GREs in the human CXCR4 transcription unit (Fig. 1) . SRC1/p300 histone acetyltransferase complex was recruited to promote histone H4 acetylation associated with CXCR4, thus facilitating transcription and expression of CXCR4 in cord blood HSCs and HPCs. Unexpectedly, CBP was not involved in this process, although in most cases, p300 and CBP function as a complex, further suggesting cell type and context specific effects of glucocorticoid signaling. There are two isoforms of CXCR4 (CXCR4-A and CXCR4-B) in human cells because of alternative splicing. The promoters of CXCR4-A and CXCR4-B are totally different. The GRE locates in the promoter of CXCR4-A and the first intron of CXCR4-B. As mRNA levels of CXCR4-A and CXCR4-B are significantly upregulated (our unpublished data), it would be interesting to know if there are functional differences between these two human CXCR4 isoforms in migration and homing of HSCs and HPCs. There is no GRE throughout the mouse Cxcr4 transcription unit, and Cxcr4 expression and SDF-1-induced chemotaxis of mouse bone marrow HSCs and HPCs remain unchanged upon glucocorticoid treatment [55 && ]. Whether glucocorticoid pretreatment of mouse bone marrow HSCs and HPCs enhances their homing and engraftment by mechanisms independent of the SDF-1/CXCR4 axis needs investigation. The PPAR family consists of three subtypes, PPARa, d/b, and g. They are ligand-dependent transcription factors regulating genes involved in energy metabolism [56] . PPARa is highly expressed in liver and other tissues/cells with a high fatty acid oxidation (FAO) rate, and mainly regulates lipid and lipoprotein metabolism [56] . Of interest, PPARa activation promotes expansion and self-renewal of erythroid progenitors [52] . Whether this process is dependent on FAO remains unknown. PPARd is mainly involved in FAO in skeletal and cardiac muscles [56] . PPARd-dependent FAO regulates asymmetric division of mouse HSC, and thus is essential for HSC maintenance [57] . PPARg is mainly expressed, but not restricted, in adipose tissue, and mediates transcription of genes involved in adipogenesis, lipid metabolism, and glucose homeostasis [26] .
In a compound screen, we found that PPARg antagonist GW9662 significantly promotes ex-vivo expansion of human cord blood HSCs and HPCs in RPMI1640 medium containing 10% fetal bovine serum (FBS) and cytokines (TPO, SCF, FLT-3L) [ FIGURE 2. PPARg functions as a negative regulator of human cord blood hematopoietic stem cell maintenance and expansion. During ex-vivo culture in regular medium (RPMI1640 with 10% FBS with cytokines), PPARg signaling is activated. Activation of PPARg increases expression of differentiation-associated genes including CD38, CD1d, HIC1, FAM20C, DUSP4, DHRS3, and ALDH1A2; and a negative regulator of glucose metabolism FBP1. HSCs/HPCs will not be well maintained and expanded because of increased differentiation and repressed glucose metabolism. Antagonizing PPARg signaling enhances maintenance and expansion of human HSCs/HPCs by preventing differentiation and switching on FBP1-repressed glycolysis [58 && ]. FBS, fetal bovine serum; HPCs, hematopoietic progenitor cells; HSCs, hematopoietic stem cells.
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blood HSCs and HPCs, whereas it has no effect on mitochondria metabolism [58 && ]. Loss of function of FBP1 was sufficient to expand cord blood HSCs and HPCs, which was dependent on glucose metabolism. Antagonizing PPARg-FBP1 signaling had no effect on expansion and glucose metabolism of cord blood HSCs and HPCs whenever CD34 þ cells were cultured in StemSpan Serum-Free Expansion Medium II (SFEM II; our unpublished data). Interestingly, expression of PPARg and FBP1 is greatly downregulated, whereas glycolysis is significantly enhanced whenever CD34 þ cells are cultured ex vivo in SFEM II compared with 10% FBS containing RPMI1640 regular medium (our unpublished data), suggesting that PPARg-FBP1 signaling is repressed by unknown ingredients in SFEM II. These findings indicate that the PPARg-FBP1 axis might function as a metabolic switch for expansion and self-renewal of cord blood HSCs and HPCs (Fig. 2) .
Inhibition of FBP1 enhances glucose metabolism in many types of cancer cells, whereas overexpression of FBP1 suppresses growth of cancer cells by compromising glycolysis [59, 60] . It is unknown if leukemia cell growth is dependent on glucose metabolism activated by suppressing FBP1, and if inhibition of FBP1 impairs mitochondria metabolism in leukemia. PPARg agonist glitazones decreases expression of STAT5 target genes, HIF2a and CITED2, and disrupts quiescence and stemness of chronic myeloid leukemia (CML) stem cells (LSCs) [61] . Further studies are needed to determine if PPARg activation impairs glucose metabolism by increasing FBP1 expression in CML LSCs. In primates infected by human and simian immunodeficiency viruses, the multipotent potential of their HPCs is disrupted, which is dependent on repression of STAT5 by ectopic activation of PPARg [62] . Whether STAT5 signaling is involved in expansion of cord blood HSCs and HPCs by antagonizing PPARg needs study. Knockdown of PPARg in Fancd2-deficient murine HSCs significantly enhances their repopulating capability in recipient mice, whereas loss of function of PPARg in wild type murine HSCs has no significant change on their engraftment [63 & ]. PPARg antagonism has no effect on expansion of mouse bone marrow HSCs and HPCs, and does not downregulate expression of differentiation-associated genes and Fbp1 in mouse bone marrow lineage negative cells [58 && ]. PPARg and its co-activators are upregulated in human FANCD2-deficient lymphoblastic cell lines and primary Fanconi patient samples [63 & ]. Future studies should determine the possible role of FBP1-mediated glucose metabolism and mitochondria metabolism in FANCD2-deficient HSCs.
CONCLUSION
Transcriptional regulation is one key intrinsic mechanism underlying human HSC expansion and selfrenewal. As important members of transcription factors, nuclear hormone receptors including RAR, glucocorticoid receptor, and PPARg play significant roles in expansion, self-renewal, homing, and engraftment of human cord blood HSCs. Sufficient HSC numbers and efficient HSC homing are pivotal for successful clinical cord blood HCT, especially in adults. The more we know about molecular mechanisms of cord blood HSC self-renewal and homing, the better efficacy we can achieve in cord blood HCT clinical trials. Overexpression of Musashi-2 (MSI2), encoding an RNA-binding protein, significantly promotes expansion of cord blood HSCs by suppressing aryl hydrocarbon receptor (AhR) signaling [64 & ]. Simultaneous transplantation of an SR1 (AhR antagonist) expanded cord blood-derived CD34 þ cell population and an unmanipulated cord blood unit significantly promoted faster recovery of neutrophils and platelets after infusion [17 & ]. It would be of interest to determine the efficacy of combining SR1 with nuclear hormone receptor ligands, especially the homing enhancer Flonase in cord blood HCT. Recently, transplantable human HSCs have been successfully reprogrammed from iPS and endothelial cells [65, 66 && ]. Can engraftment of these reprogrammed HSCs be enhanced by modulating nuclear hormone receptor signaling? As many nuclear hormone receptor ligands are FDAapproved drugs, nuclear hormone receptors represent promising targets for enhancing engraftment of human cord blood HCT.
